Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tavaborole 5% Topical Solution in Pediatric Onychomycosis
NCT03405818Phase 4Completed
- Sponsor
- Pfizer
- Start
- Oct 2015
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tavaborole in onychomycosis, sponsored by Pfizer. Primary endpoints: Number of Participants With Local Tolerability Reactions by Severity at Week 52, Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) at Week 52 and 4 more. Started Oct 2015; status: completed.
02
Drugs
tavaborole
03
Conditions
onychomycosis
Beyond the preview
Go deeper on NCT03405818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03405818.